IAAG
GMAB icon

Innovative Asset Advisors Group’s Genmab GMAB Stock Holding History

Innovative Asset Advisors Group’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-151
Closed -$4.05K – 584
2026
Q1 		$4.05K Buy
+151
New +$4.53K ﹤0.01% 807

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Innovative Asset Advisors Group's GMAB Position: Q2 2026 in Review

Innovative Asset Advisors Group sold out of Genmab (GMAB) in Q2 2026, closing a stake of 151 shares — an estimated $4.05K sold.

Innovative Asset Advisors Group first reported a position in GMAB in Q1 2026 and held it in 1 quarter. The position peaked at $4.05K in Q1 2026. 276 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Innovative Asset Advisors Group reported no remaining Genmab position as of Q2 2026 after selling out during the quarter.
  • Innovative Asset Advisors Group sold 151 Genmab shares in Q2 2026, an estimated $4.05K.
  • Innovative Asset Advisors Group first reported a position in Genmab in Q1 2026 and held it in 1 quarter.
  • Innovative Asset Advisors Group's Genmab position peaked at $4.05K in Q1 2026.
  • 276 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Innovative Asset Advisors Group's 13F filing for Q2 2026, filed 5 Aug 2026.